Furukawa K, Yamaguchi H, Oettgen H F, Old L J, Lloyd K O
Memorial Sloan-Kettering Cancer Center, New York, New York 10021.
Cancer Res. 1989 Jan 1;49(1):191-6.
The fine specificity analysis of two human monoclonal antibodies (AbFCM1 and AbHJM1) reacting with gangliosides is described and their specificities are compared with analogous mouse monoclonal antibodies (mAbs). These two antibodies were generated from lymphocytes of melanoma patients by Epstein-Barr virus transformation followed by fusion with mouse myeloma NS-1. Using a wide variety of gangliosides, including N-glycolylneuraminic acid (NeuGc)-containing compounds, the precise structures recognized by these two antibodies were elucidated by enzyme-linked immunosorbent assay and immunostaining of thin-layer chromatograms. AbFCM1 reacted with N-acetylneuraminic acid (NeuAc)-type GM3, GD1a, sialylparagloboside, and GT1b in decreasing order of intensity. This antibody also reacted with (NeuAc-NeuGc-)-GD3 and -disialylparagloboside, but did not react with NeuGc-type GM3, GM2, sialylparagloboside, (NeuGc)2-GD3 and -disialylparagloboside. The main epitope structures recognized by AbFCM1 are, therefore, NeuAc alpha 2----3Gal beta 1- and NeuAc alpha 2----8NeuGc alpha 2----Gal beta 1-. These results are similar to the specificity of mouse mAb M2590. AbHJM1 reacted with NeuAc-type GD3 and disialylparagloboside, GD2, GD1b, GM3, and GT1b, in decreasing order of intensity. Among NeuGc-type gangliosides, this antibody reacts with (NeuAc-NeuGc-)-GD3 and -disialylparagloboside, but did not react with gangliosides containing only NeuGc. Consequently the epitope structure recognized by AbHJM1 is probably (R)-(NeuAc alpha 2----8Sialic acid alpha 2----3)Gal beta 1-. Mouse anti-GD3 mAbR24, in contrast, showed strong reactivity only with GD3 and -disialylparagloboside among NeuAc-type gangliosides, but showed a similar pattern to AbHJM1 in its reactivity with NeuGc-containing gangliosides. Although these two human monoclonal antibodies are not highly restricted in their specificities, they reacted best with the major gangliosides, GM3 and GD3, present in the majority of human melanomas.
描述了两种与神经节苷脂反应的人源单克隆抗体(AbFCM1和AbHJM1)的精细特异性分析,并将它们的特异性与类似的小鼠单克隆抗体(mAb)进行了比较。这两种抗体是通过爱泼斯坦-巴尔病毒转化黑色素瘤患者的淋巴细胞,然后与小鼠骨髓瘤NS-1融合而产生的。使用多种神经节苷脂,包括含N-羟乙酰神经氨酸(NeuGc)的化合物,通过酶联免疫吸附测定和薄层色谱图的免疫染色阐明了这两种抗体识别的精确结构。AbFCM1与N-乙酰神经氨酸(NeuAc)型GM3、GD1a、唾液酸副球蛋白和GT1b反应,强度依次降低。该抗体还与(NeuAc-NeuGc-)-GD3和-二唾液酸副球蛋白反应,但不与NeuGc型GM3、GM2、唾液酸副球蛋白、(NeuGc)2-GD3和-二唾液酸副球蛋白反应。因此,AbFCM识别 的主要表位结构是NeuAcα2----3Galβ1-和NeuAcα2----8NeuGcα2----Galβ1-。这些结果与小鼠单克隆抗体M2590的特异性相似。AbHJM1与NeuAc型GD3、二唾液酸副球蛋白、GD2、GD1b、GM3和GT1b反应,强度依次降低。在NeuGc型神经节苷脂中,该抗体与(NeuAc-NeuGc-)-GD3和-二唾液酸副球蛋白反应,但不与仅含NeuGc的神经节苷脂反应。因此,AbHJM1识别的表位结构可能是(R)-(NeuAcα2----8唾液酸α2----3)Galβ1-。相比之下,小鼠抗GD3单克隆抗体R24在NeuAc型神经节苷脂中仅与GD3和-二唾液酸副球蛋白有强烈反应,但在与含NeuGc的神经节苷脂反应方面与AbHJM1表现出相似的模式。尽管这两种人源单克隆抗体的特异性没有高度受限,但它们与大多数人类黑色素瘤中存在的主要神经节苷脂GM3和GD3反应最佳。